Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)

Next Previous
Trial Profile

Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STC 1010 (Primary) ; Bevacizumab; Cyclophosphamide; Fluorouracil; Folinic acid; Granulocyte macrophage colony stimulating factor; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms BreAK-CRC
  • Sponsors Brenus Pharma

Most Recent Events

  • 11 Jul 2025 Status changed from not yet recruiting to recruiting.
  • 23 Apr 2025 Status changed from planning to not yet recruiting.
  • 13 Jun 2024 According to a Brenus Pharma media release, the company announced that BreAK-CRC trial protocol has been reviewed in pre-submission meeting with the French National Health Authority. The submission of the CTA through the clinical trial information system of the European union is ongoing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top